F9181

Anti-FRAT1 (C-terminal region) antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

• 别名: Anti-Frequently rearranged in advanced T-cell lymphomas, Anti-GBP, Anti-GSK-3 binding protein
• 分類程式碼代碼: 12352203
• NACRES: NA.41

属性

• 生物源: rabbit
• 共軛: unconjugated
• 抗體表格: affinity isolated antibody
• 抗體產品種類: primary antibodies
• 無性繁殖: polyclonal
• 形狀: buffered aqueous solution
• 分子量: antigen ~29 kDa
• 物種活性: human
• 濃度: ~1.5 mg/mL
• 技術: western blot: 1-2 μg/mL using HEK-293T cell lysate expressing human FRAT1
• UniProt登錄號: Q92837
• 運輸包裝: dry ice
• 儲存溫度: −20°C
• 基因資訊: human ... FRAT1(10023)

说明

一般說明

FRAT1 (frequently rearranged in advanced T-cell lymphomas-1) is a GSK3β binding protein consisting of a conserved GSK3β interacting domain. In human two FRAT genes have been identified, FRAT1 and FRAT2 whereas FRAT1-3 have been identified in mouse.

應用

Anti-FRAT1 (C-terminal region) antibody is suitable for western blot at a concentration of 1-2μg/mL using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.

生化／生理作用

By inhibiting GSK-3-mediated phosphorylation of β-catenin, FRAT1 plays a major role in the wnt-signaling pathway. During binding to the GSKβ3, it competes with axin and thus displacing GSKβ3 from the axin-β-catenin complex. In the canonical wnt signaling pathway, FRAT1 acts more efficiently than FRAT2. FRAT1 has correlation with clinicopathologic features. It has been reported that in several human malignant tumors, FRAT is overexpressed. It′s upregulated expression have been found in several human cancer lines such as gastric cancers and esophageal squamous cell carcinoma (ESCC).

外觀

0.01M 磷酸缓冲盐溶液，pH 7.4，含 15mM 叠氮化钠。